Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods

被引:27
作者
Wan, Fei [1 ]
Small, Dylan [2 ]
Bekelman, Justin E. [3 ]
Mitra, Nandita [1 ]
机构
[1] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Stat, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA
关键词
instrumental variable; two-stage residual inclusion; two-stage predictor substitution; unmeasured confounding; survival; bias; ADVANCED PROSTATE-CANCER; ANDROGEN-DEPRIVATION THERAPY; INFERENCE; MODELS; IDENTIFICATION; NONCOMPLIANCE; RADIOTHERAPY; TRIAL;
D O I
10.1002/sim.6470
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two-stage instrumental variable methods are commonly used to estimate the causal effects of treatments on survival in the presence of measured and unmeasured confounding. Two-stage residual inclusion (2SRI) has been the method of choice over two-stage predictor substitution (2SPS) in clinical studies. We directly compare the bias in the causal hazard ratio estimated by these two methods. Under a principal stratification framework, we derive a closed-form solution for asymptotic bias of the causal hazard ratio among compliers for both the 2SPS and 2SRI methods when survival time follows the Weibull distribution with random censoring. When there is no unmeasured confounding and no always takers, our analytic results show that 2SRI is generally asymptotically unbiased, but 2SPS is not. However, when there is substantial unmeasured confounding, 2SPS performs better than 2SRI with respect to bias under certain scenarios. We use extensive simulation studies to confirm the analytic results from our closed-form solutions. We apply these two methods to prostate cancer treatment data from Surveillance, Epidemiology and End Results-Medicare and compare these 2SRI and 2SPS estimates with results from two published randomized trials. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:2235 / 2265
页数:31
相关论文
共 19 条
  • [11] Rubin D. B., 1990, STAT SCI, V5, P472, DOI DOI 10.1214/SS/1177012032
  • [14] STRUTHERS CA, 1986, BIOMETRIKA, V73, P363
  • [15] Tans HJ, 2012, JAMA-J AM MED ASSOC, V307, P1629
  • [16] Causal logistic models for non-compliance under randomized treatment with univariate binary response
    Ten Have, TR
    Joffe, M
    Cary, M
    [J]. STATISTICS IN MEDICINE, 2003, 22 (08) : 1255 - 1283
  • [17] Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling
    Terza, Joseph V.
    Basu, Anirban
    Rathouz, Paul J.
    [J]. JOURNAL OF HEALTH ECONOMICS, 2008, 27 (03) : 531 - 543
  • [18] Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    Warde, Padraig
    Mason, Malcolm
    Ding, Keyue
    Kirkbride, Peter
    Brundage, Michael
    Cowan, Richard
    Gospodarowicz, Mary
    Sanders, Karen
    Kostashuk, Edmund
    Swanson, Greg
    Barber, Jim
    Hiltz, Andrea
    Parmar, Mahesh K. B.
    Sathya, Jinka
    Anderson, John
    Hayter, Charles
    Hetherington, John
    Sydes, Matthew R.
    Parulekar, Wendy
    [J]. LANCET, 2011, 378 (9809) : 2104 - 2111
  • [19] Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
    Widmark, Anders
    Klepp, Olbjorn
    Solberg, Arne
    Damber, Jan-Erik
    Angelsen, Anders
    Fransson, Per
    Lund, Jo-Asmund
    Tasdemir, Ilker
    Hoyer, Morten
    Wiklund, Fredrik
    Fossa, Sophie D.
    [J]. LANCET, 2009, 373 (9660) : 301 - 308